Precision BioSciences Receives FDA IND Clearance for DMD Gene Therapy, Advancing to Phase 1/2 Study
DTIL is trading near its 52-week low of $3.53 (13% above the low) on light trading volume (0.4× avg).
Summary
Precision BioSciences announced FDA IND clearance for its PBGENE-DMD program for Duchenne muscular dystrophy, allowing the company to proceed with a Phase 1/2 clinical study.
Key Events · Product Development and Regulatory · DTIL
-
FDA IND Clearance Received
The U.S. Food and Drug Administration (FDA) issued a 'Study May Proceed' notification for Precision BioSciences' Investigational New Drug (IND) application for PBGENE-DMD.
-
Phase 1/2 Clinical Study Initiation
The IND clearance enables the company to initiate clinical trial site activities for the FUNCTION-DMD Phase 1/2 clinical study for ambulatory Duchenne muscular dystrophy (DMD) patients.
-
First-in-Class Gene Editing Approach
PBGENE-DMD is a wholly-owned, first-in-class in vivo gene editing program utilizing a gene excision approach to correct the underlying genetic cause of DMD in patients with mutations between exons 45 and 55, representing approximately 60% of DMD patients.
-
Upcoming Investor Event
Precision BioSciences plans to host a virtual investor event in March 2026 to discuss the PBGENE-DMD program and the FUNCTION-DMD clinical study, with participation from key opinion leaders.
Analysis · DTIL · Life Sciences
Precision BioSciences has achieved a significant regulatory milestone with the FDA's clearance of its Investigational New Drug (IND) application for PBGENE-DMD, a gene editing program targeting Duchenne muscular dystrophy (DMD). This clearance enables the company to initiate its FUNCTION-DMD Phase 1/2 clinical study, marking a critical step forward in the development of this potential first-in-class therapy. The program is designed to address the underlying genetic cause of DMD in a substantial portion of patients (those with mutations between exons 45 and 55), aiming to restore near full-length dystrophin protein. Successful progression through clinical trials could significantly de-risk the program and provide a much-needed treatment option for DMD patients.
At the time of this filing, DTIL was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.5M. The 52-week trading range was $3.53 to $8.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.